GLP-1 Daily: Ozempic & Wegovy News
Death Reports Name Bootleg Retatrutide; Walmart's Free GLP-1s Skip Weight Loss
Wednesday, October 14, 2026 · 6 min
CBS News obtained two unverified FDA adverse-event reports of deaths after use of products sold as retatrutide, and Walmart will make Ozempic and Mounjaro free in 2027 for employees with type 2 diabetes but still won't cover GLP-1s for weight loss. Plus, a new Annals of Internal Medicine paper finds the Wegovy pill passed 100,000 monthly new prescriptions within two months of launch.
Listen
Show notes
CBS News obtained two unverified FDA adverse-event reports of deaths after use of products sold as retatrutide, and Walmart will make Ozempic and Mounjaro free in 2027 for employees with type 2 diabetes but still won't cover GLP-1s for weight loss. Plus, a new Annals of Internal Medicine paper finds the Wegovy pill passed 100,000 monthly new prescriptions within two months of launch.
In this episode
- Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? - CBS News — Daniel Gilbert Investigative Reporter
“The cases appear to be the first public accounts in the U.S. alleging that unauthorized use of retatrutide — or products claiming to contain it — played a role in a patient's death, though the details aren't verified and it is unclear whether the drug was to blame.”
- Walmart employee benefits add no-cost GLP-1s in 2027 — CNBC
“Walmart plans to cover more than 250 prescriptions, including some insulin, inhalers and GLP-1s for diabetes, at no cost to its employees, in 2027, the company confirmed to CNBC.”
- Oral Semaglutide Obesity Rx Tops 100K Monthly in 2 Months — Medscape
“Within 2 months of launch, the oral semaglutide pill surpassed 100,000 monthly new prescriptions. Tirzepatide took 4 months to reach that mark, and injectable semaglutide took 20 months.”